YDYilun Deng

Yilun Deng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yilun Deng has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Redox Imbalance in Chronic Inflammatory Diseases

    by Ziqing Li, Dongliang Xu, Xinhua Li, Yilun Deng, Chaohong Li

    Redox homeostasis, a crucial determinant of physiological processes that maintain the health of cellular function, is intimately relying on the balance between prooxidative productions and concomitant antioxidant defense system [1, 2]. Often caused by an aggressive accumulation of reactive oxygen species (ROS) or weakened antioxidant defenses in multiple organs, stubborn redox imbalance is one of the notorious features in patients suffering from chronic inflammatory diseases [2]. ROS are produced in all cell types as byproducts of the mitochondrial electron transport chain (ETC) during ATP synthesis or formed by NADPH oxidase (NOX) in a controlled manner for targeted purposes such as the respiratory burst in macrophages and neutrophils against microbial invasion [3]. In turn, organisms have evolved several defense mechanisms to detoxify ROS, ranging from transcription factors to enzymes that elevated intracellular antioxidative defenses [4, 5]. Also, many natural products and organic compounds demonstrate a prominent protective effect of antioxidants on targeted tissues, contributing to the relief of chronic inflammatory symptoms in patients [6]. Therefore, understanding the complicated relationship between redox regulation and concomitant inflammatory consequences, from a molecular basis to tissue levels, represents a significant challenge for developing efficient therapeutics for chronic inflammatory diseases. This special issue is aimed at presenting recent research efforts in both molecular and macro mechanisms of redox regulation during the chronic inflammatory process and the novel role of antioxidant factors in protecting organs from chronic inflammatory damage.


  • Open Access

    Targeting Ovarian Cancer with IL-2 Cytokine/Antibody Complexes: A Summary and Recent Advances

    by Yilun Deng, Ryan M Reyes, Chenghao Zhang, José Conejo-Garcia, Tyler J. Curiel


  • Open Access

    Association between Plasma Osmolality and Case Fatality within 1 Year after Severe Acute Ischemic Stroke

    by Meng Liu, Yilun Deng, Yajun Cheng, Zilong Hao, Simiao Wu, Ming Liu

    Liu M, et al. Yonsei Med J. 2021 Jul;62(7):600-607. https://doi.org/10.3349/ymj.2021.62.7.600


  • Open Access

    690 CD122-selective IL-2 complexes treat ovarian carcinomas, induce Treg fragility and promote T cell stem cells

    by Yilun Deng, Justin Drerup, Xinyue Zhang, Ryan Reyes, Jenny Mendez, Aravind Kancharla, Myrna Garcia, Haiyan Bai, Alvaro Padron, Harshita Gupta, et al.

    Background Ovarian cancer (OC) responds poorly to immunotherapies. Regulatory T cells (Treg) engage IL-2 by high-affinity CD25 for differentiation and function,1 and anti-tumor effector T cells (Teff) use intermediate affinity CD122. We studied IL-2 complexes (IL-2c) that selectively activate CD122 (Teff) over CD25 (Tregs). Methods Orthotopic ID8agg-luc mouse OC burden was measured by in vivo imaging. Tumor, ascites and draining lymph nodes (TDLN) were analyzed by flow and tSNE. IL-2c was complexed using 1.5 µg/mouse IL-2 and 7.5 µg/mouse aIL-2 (clone JES6-5H4) before i.p. injection every other day x 4 starting at day 7. antiPD-L1 was given at 100ug/mouse every 3 days x 4 starting from Day 11. FIR mice2 were used to sort live Tregs. Results IL-2c but not antiPD-L1 potently inhibits ID8agg (figure 1). IL-2c decreased ascites Treg functional markers (e.g., CD25, granzymeB) while upregulating the same markers on Teffs (figure 2). IL-2c inhibited Treg suppression in ascites while TDLN Tregs were unaffected (figure 3). tSNE showed great similarity of TDLN Tregs treated with isotype and IL-2c while ascites Tregs after IL-2c showed a fragile phenotype (e.g., increased PD-1, T-bet, and IFNgamma with maintained FoxP3 expression [figure 4]) which is known to contribute to better response to cancer immunotherapy.3 4 We observed a complete reduction of tumor bioluminescence with IL-2c and antiPD-L1 combo treatment in nearly all subjects significantly exceeding effect of IL-2c alone (figure 5). A CD8+CXCR5+TCF-1+ T cell stem cell (TCSC) population reportedly improves immune checkpoint blockade efficacy.5 6 Since CD122 is regulated by TCF-1,7 we explored the effect of IL-2c on these TCSC. IL-2c significantly induced a CD8+TCF-1+ TCSC population in ID8agg tumors (figure 6), possibly through a positive feedback loop by further enhancing CD122 expression on TCF-1+, but not TCF-1- cells (figure 7). tSNE analysis of detailed immune phenotype of IL-2c induced TCSC revealed that these TCSC differed from those induced by antiPD-L1. In ID8agg, antiPD-L1-induced TCSC are mostly CXCR5+ and PD1+, consistent with previous reports in other cancers3 4 while IL-2c-induced TCSC were PD1- (figure 8), expressed CCR2 and CXCR3, and produced TNFalpha (figure 9). IL-2c but not aPD-L1 treats ID8aggLuciferase signal of ID8agg-luc tumors treated with isotype, ?PD-L1, or IL-2c measured by in vivo imaging. Arrows indicate treatments. IL-2c inhibits functional markers on tregs and promotes teffExpression of CD25 and granzymeB were measured by flow cytometry in indicated population from isotype or IL-2c treated ascites 3 weeks after final IL-2c dose. IL-2c reduces ascites Treg suppressive functionTregs sorted from ascites or TDLN of isotype or IL-2c treated FIR mice co-cultured with Teff cells. Percent suppression of Teff cells proliferation shown. IL-2c induces Treg fragility in ascites but not TDLN tSNE analysis on CD45+CD3+CD4+FoxP3+ cells from ascites and TDLN of isotype and IL-2c treated ID8agg-luc challenged mice. Right, representative bar graphs of flow data. IL-2c and aPD-L1 combo treatment effectively cures ID8aggLuciferase signal of ID8agg-luc tumors treated with isotype, ?PD-L1, IL-2c or combo measured by in vivo imaging. Arrows indicate treatments. IL-2c induces a CD8+TCF-1+ population in ID8aggID8agg-luc tumors analyzed by flow cytometry gated on CD45+CD3+CD8+ cells. IL-2c induces CD122 on CD8+TCF-1+ but not TCF-1- cellsCD122 expression was measured by flow cytometry in CD8+TCF-1+ and CD8+ TCF-1- cells from tumors treated with isotype or IL-2c. CD8+TCF1+ cells from ID8agg analyzed by flow cytometry plus tSNE. Cells expressing CXCR5 (blue) and PD1 (red) indicated in overlay CD8+TCF1+ cells from ID8agg analyzed by flow cytometry Conclusions We define two novel IL-2c effects: inducing Treg fragility therefore reducing immunosuppression while promoting TCSC that could enhance effective anti-tumor immunity. Current work tests if effects are related and help efficacy, and mechanisms for IL-2c Treg effects. We also show that elicited TCSC differ by treatment and tumor, requiring additional investigations. Acknowledgements This work is supported by CPRIT Research Training Award (RP 170345), Ovarian Cancer Research Alliance Ann and Sol Schreiber Mentored Investigator Award to YD and R01 CA205965to TC. Ethics Approval All mice studies were approved by UT Health San Antonio Institutional Animal Care and Use Committee (IACUC). Approval number 20150093AR, 20140001AR, 20170035AR, 20140039AR, 20140027AR, 20090128AR, 20120071AR, 20180021AR. References Malek TR: The biology of interleukin-2. Annu Rev Immunol 2008, 26:453–479. Fantini MC, Dominitzki S, Rizzo A, Neurath MF, Becker C: In vitro generation of CD4+ CD25+ regulatory cells from murine naive T cells. Nat Protoc 2007, 2(7):1789–1794. Overacre-Delgoffe AE, Chikina M, Dadey RE, Yano H, Brunazzi EA, Shayan G, Horne W, Moskovitz JM, Kolls JK, Sander C, et al: Interferon-gamma Drives Treg Fragility to Promote Anti-tumor Immunity. Cell 2017, 169(6):1130–1141e1111. Overacre-Delgoffe AE, Vignali DAA: Treg Fragility: A Prerequisite for Effective Antitumor Immunity? Cancer Immunol Res 2018, 6(8):882–887. Brummelman J, Mazza EMC, Alvisi G, Colombo FS, Grilli A, Mikulak J, Mavilio D, Alloisio M, Ferrari F, Lopci E, et al: High-dimensional single cell analysis identifies stem-like cytotoxic CD8(+) T cells infiltrating human tumors. J Exp Med 2018. Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, et al: Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell 2018, 175(4):998–1013 e1020. Jeevan-Raj B, Gehrig J, Charmoy M, Chennupati V, Grandclement C, Angelino P, Delorenzi M, Held W: The Transcription Factor Tcf1 Contributes to Normal NK Cell Development and Function by Limiting the Expression of Granzymes. Cell Rep 2017, 20(3):613–626.


  • Open Access

    Osteoimmunology in Bone Regeneration

    by Ziqing Li, Puyi Sheng, Chaohong Li, Gongsheng Yuan, Yilun Deng

    Bone has the unique capacity to heal bony injuries without fibrous scar formation via its regeneration process and therefore maintains physiological and mechanical characteristics. This continuous and well-orchestrated regeneration process is also critical for the upkeep of calcium homeostasis throughout one’s lifetime [1, 2]. Stimulating bone regeneration is the central aim in orthopedic surgery and in oral and maxillofacial surgery, in order to overcome large bone defects and to cure metabolic/inflammatory bone diseases. Although tissue-engineered materials or artificial bone can help to retain bone stability, biocompatibility and bioresorbability are still significant obstacles for biomaterials to achieve so as to sync with the natural regeneration process. During recent decades, advances in this field have begun to reveal various regulatory molecules shared by the immune system and skeletal system, which depict interesting crosstalk of signaling transducers between immune cells and bone cells [3, 4]. Therefore, osteoimmunology has developed as an essential interdisciplinary field underlying major discoveries concerning bone regeneration and developing targeted therapies for bone diseases. This special issue is aimed at presenting recent research efforts in the crosstalk between the immune system and the skeletal system and their potential application for bone regeneration.